Novakand Pharma AB (publ)

OM:NOVKAN Stock Report

Market Cap: SEK 27.4m

Novakand Pharma Future Growth

Future criteria checks 0/6

Novakand Pharma's revenue and earnings are forecast to decline at 23.7% and 33.1% per annum respectively.

Key information

-33.1%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth38.0%
Revenue growth rate-23.7%
Future return on equityn/a
Analyst coverage

Low

Last updated27 May 2025

Recent future growth updates

Recent updates

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Aug 13
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Dec 06
We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Jul 19
Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Mar 08
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Jun 29
We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Aug 02
Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Apr 06
We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Earnings and Revenue Growth Forecasts

OM:NOVKAN - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20270-55N/A-551
12/31/202620-36N/A-361
12/31/202530-5N/A-141
6/30/2025N/A-40-48-48N/A
3/31/2025N/A-45-53-53N/A
12/31/2024N/A-45-59-59N/A
9/30/2024N/A-53-60-60N/A
6/30/2024N/A-53-51-51N/A
3/31/2024N/A-60-51-51N/A
12/31/2023N/A-65-56-56N/A
9/30/2023N/A-60-52-52N/A
6/30/2023N/A-61-58-58N/A
3/31/2023N/A-58-57-57N/A
12/31/2022N/A-52-48-48N/A
9/30/2022N/A-51-53-53N/A
6/30/2022N/A-52-50-50N/A
3/31/2022N/A-49-44-44N/A
12/31/2021N/A-46-44-44N/A
9/30/2021N/A-45-41-41N/A
6/30/20210-44-39-39N/A
3/31/20210-38-39-39N/A
12/31/20200-40-39-39N/A
9/30/20200-35-29-29N/A
6/30/20200-34-29-29N/A
3/31/20200-40-36-36N/A
12/31/20193-36-33-33N/A
9/30/20194-41-46-46N/A
6/30/20193-44-53-53N/A
3/31/20193-41N/A-41N/A
12/31/20180-46N/A-45N/A
9/30/20180-46N/A-50N/A
6/30/20180-52N/A-41N/A
3/31/20180-59N/A-54N/A
12/31/20170-56N/A-54N/A
9/30/20170-51N/A-41N/A
6/30/20170-39N/A-40N/A
3/31/20170-27N/A-26N/A
12/31/20160-22N/A-23N/A
9/30/20160-22N/A-22N/A
6/30/20160-20N/A-19N/A
3/31/20160-20N/A-22N/A
12/31/20150-20N/A-21N/A
9/30/20150-19N/A-24N/A
6/30/20150-18N/A-23N/A
3/31/20150-17N/A-21N/A
12/31/20140-16N/A-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NOVKAN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NOVKAN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NOVKAN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NOVKAN's revenue is expected to decline over the next 3 years (-23.7% per year).

High Growth Revenue: NOVKAN's revenue is forecast to decline over the next 3 years (-23.7% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NOVKAN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/30 16:24
End of Day Share Price 2025/10/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novakand Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Johan StromqvistABG Sundal Collier Sponsored
Martin WahlstromRedeye
Filip LindkvistRedeye